UroGen Pharma Ltd. (URGN)

36.33
NASDAQ : Health Technology
Prev Close 36.00
Day Low/High 34.72 / 36.57
52 Wk Low/High 30.48 / 55.49
Avg Volume 212.90K
Exchange NASDAQ
Shares Outstanding 20.90M
Market Cap 752.33M
EPS -4.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

UroGen Pharma Reports Second Quarter 2019 Financial Results And Recent Corporate Developments

UroGen Pharma Reports Second Quarter 2019 Financial Results And Recent Corporate Developments

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the second quarter ended June 30, 2019 and provided an overview of the...

UroGen Pharma To Report Second Quarter 2019 Financial Results On Friday, August 9, 2019

UroGen Pharma To Report Second Quarter 2019 Financial Results On Friday, August 9, 2019

UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report second quarter 2019 financial results on Friday, August 9, 2019, prior to the open of the market.

UroGen Pharma Joins Russell 3000® Index

UroGen Pharma Joins Russell 3000® Index

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it joined the broad-market Russell 3000 ® Index at the conclusion of the 2019 Russell indexes...

UroGen Pharma To Present At June 2019 Investor Conferences

UroGen Pharma To Present At June 2019 Investor Conferences

UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at three investor conferences in June: Jefferies 2019 Global Healthcare Conference Tuesday, June 4th 9:00AM Eastern Time New York, NY Goldman Sachs 40 th Annual Global...

UroGen Pharma Reports First Quarter 2019 Financial Results And Recent Corporate Developments

UroGen Pharma Reports First Quarter 2019 Financial Results And Recent Corporate Developments

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the first quarter ended March 31, 2019 and provided an overview of the...

UroGen Delivers Updated Complete Response (CR) And Durability Data From The UGN-101 Phase 3 OLYMPUS Trial

UroGen Delivers Updated Complete Response (CR) And Durability Data From The UGN-101 Phase 3 OLYMPUS Trial

UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced findings from a secondary analysis from the pivotal Phase 3 OLYMPUS trial which showed that...

UroGen Pharma To Report First Quarter 2019 Financial Results On Thursday, May 9, 2019

UroGen Pharma To Report First Quarter 2019 Financial Results On Thursday, May 9, 2019

UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the market.

UroGen Pharma Announces Early Stage Feasibility Agreement With Janssen

UroGen Pharma Announces Early Stage Feasibility Agreement With Janssen

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an agreement with Janssen Research & Development, LLC...

UroGen Pharma Announces Presentation Of Analysis From Phase 3 OLYMPUS Trial Of UGN-101 For Patients With Low-Grade Upper Tract Urothelial Cancer

UroGen Pharma Announces Presentation Of Analysis From Phase 3 OLYMPUS Trial Of UGN-101 For Patients With Low-Grade Upper Tract Urothelial Cancer

UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced a new presentation from the pivotal Phase 3 OLYMPUS trial of UGN-101 (mitomycin gel) for...

UroGen Pharma To Present At March 2019 Investor Conferences

UroGen Pharma To Present At March 2019 Investor Conferences

UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March: Cowen and Company 39 th Annual Health Care Conference Tuesday, March 12 th 11:20AM Eastern Time Boston, MA Oppenheimer 29 th Annual...

Oversold Conditions For UroGen Pharma (URGN)

Oversold Conditions For UroGen Pharma (URGN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

UroGen Pharma To Report Fourth Quarter And Full Year 2018 Financial Results

UroGen Pharma To Report Fourth Quarter And Full Year 2018 Financial Results

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the fourth quarter and full year ended December 31, 2018 and provided an...

UroGen Pharma To Report Fourth Quarter And Full Year 2018 Financial Results On Thursday, February 28, 2019

UroGen Pharma To Report Fourth Quarter And Full Year 2018 Financial Results On Thursday, February 28, 2019

UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019, prior to the open of the market.

UroGen Pharma Announces Closing Of Public Offering Of Ordinary Shares And Full Exercise Of Underwriters' Option To Purchase Additional Shares

UroGen Pharma Announces Closing Of Public Offering Of Ordinary Shares And Full Exercise Of Underwriters' Option To Purchase Additional Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the closing of its previously announced public offering of...

UroGen Pharma Announces Pricing Of Public Offering Of Ordinary Shares

UroGen Pharma Announces Pricing Of Public Offering Of Ordinary Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the pricing of its public offering of 3,658,537 ordinary...

UroGen Pharma Announces Proposed Public Offering Of Ordinary Shares

UroGen Pharma Announces Proposed Public Offering Of Ordinary Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary...

UroGen Pharma Announces Positive Results Of UGN-101 From Pivotal Phase 3 OLYMPUS Trial For The Non-Surgical Treatment Of Patients With Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

UroGen Pharma Announces Positive Results Of UGN-101 From Pivotal Phase 3 OLYMPUS Trial For The Non-Surgical Treatment Of Patients With Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced topline results from the ongoing pivotal Phase 3 OLYMPUS clinical trial of UGN-101...

UroGen Pharma Appoints Elizabeth (Liz) Barrett As President And Chief Executive Officer

UroGen Pharma Appoints Elizabeth (Liz) Barrett As President And Chief Executive Officer

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointment of Elizabeth (Liz) Barrett as President and...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DNR, EXEL, GIL, HF, ITGR, TEF Downgrades: CERC, FSB, PED, QTNA Initiations: URGN Read on to get TheStreet Quant Ratings' detailed report:

UroGen Pharma Initiates Rolling Submission Of New Drug Application (NDA) For UGN-101 For The Treatment Of Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

UroGen Pharma Initiates Rolling Submission Of New Drug Application (NDA) For UGN-101 For The Treatment Of Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced that it has initiated the rolling submission with the U.

UroGen Pharma Reports Third Quarter 2018 Financial Results And Completed UGN-101 OLYMPUS Trial Enrollment

UroGen Pharma Reports Third Quarter 2018 Financial Results And Completed UGN-101 OLYMPUS Trial Enrollment

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced financial results for third quarter ended September 30, 2018...

UroGen Pharma To Present At November 2018 Investor Conferences

UroGen Pharma To Present At November 2018 Investor Conferences

UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in November 2018: Stifel 2018 Healthcare Conference Tuesday, November 13 9:30AM Eastern Time New York, NY Jefferies 2018 London Healthcare...

UroGen Pharma To Report Third Quarter 2018 Financial Results On Monday, November 12, 2018

UroGen Pharma To Report Third Quarter 2018 Financial Results On Monday, November 12, 2018

UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report third quarter 2018 financial results on Monday, November 12, 2018, prior to the open of the market.

FDA Grants Breakthrough Therapy Designation (BTD) For UroGen Pharma's UGN-101 For The Treatment Of Patients With Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

FDA Grants Breakthrough Therapy Designation (BTD) For UroGen Pharma's UGN-101 For The Treatment Of Patients With Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that the U.

UroGen Pharma To Present At The Ladenburg Thalmann 2018 Healthcare Conference

UroGen Pharma To Present At The Ladenburg Thalmann 2018 Healthcare Conference

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, Chief Executive Officer, will present at the...

Jones "Woody" Bryan Joins UroGen Pharma As Senior Vice President Of Business Development

Jones "Woody" Bryan Joins UroGen Pharma As Senior Vice President Of Business Development

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company, today announced that Jones "Woody" Bryan, Ph.

UroGen Pharma Enters Oversold Territory (URGN)

UroGen Pharma Enters Oversold Territory (URGN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

RSI Alert: UroGen Pharma (URGN) Now Oversold

RSI Alert: UroGen Pharma (URGN) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D+ (Sell)